Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M4\KVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr4XXVKSzVyPUCuNFI5ODZizszN MlXuV2FPT0WU
KS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvScXhKSzVyPUCuNFM5OzVizszN M{G4O3NCVkeHUh?=
TE-11 MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV71S3Y3UUN3ME2wMlA4QDJ{IN88US=> MYfTRW5ITVJ?
EW-1 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMEi1PFUh|ryP MX7TRW5ITVJ?
HMV-II MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17iTGlEPTB;MD6wPFg1PiEQvF2= MVfTRW5ITVJ?
COLO-205 NXHWWopHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\6TWM2OD1yLkGwOFU1KM7:TR?= MoGzV2FPT0WU
ES1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMUC2PVYh|ryP NEnidmNUSU6JRWK=
GDM-1 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[zTWM2OD1yLkGzOlczKM7:TR?= NELkSmpUSU6JRWK=
ML-2 NYLmdol2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLOSHdKSzVyPUCuNVU5QTZizszN MmHmV2FPT0WU
Saos-2 NFLVbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\zTWM2OD1yLkG2OVI3KM7:TR?= NY\5WIdnW0GQR1XS
NCI-H1355 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH1eJg1UUN3ME2wMlE5OTN3IN88US=> MUHTRW5ITVJ?
G-401 NHfr[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XuZmlEPTB;MD6xPFI{KM7:TR?= MYLTRW5ITVJ?
EW-16 NWXOOmR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn64TWM2OD1yLkG4O|c4KM7:TR?= MWTTRW5ITVJ?
EW-7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfhTWM2OD1yLkG4PFgyKM7:TR?= NUj2N5Z7W0GQR1XS
NCI-H727 M1LrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13wWWlEPTB;MD6xPVc6PCEQvF2= NVfycoRRW0GQR1XS
LCLC-97TM1 NVjjOI9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjtPWFKSzVyPUCuNlA6PTVizszN NFnz[WtUSU6JRWK=
NCI-H650 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7H[nhKSzVyPUCuNlE{QDRizszN NUn1WWFuW0GQR1XS
NCI-H2122 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLRTWM2OD1yLkKzNlk6KM7:TR?= NILzem5USU6JRWK=
SK-N-DZ NV7OfmFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;ZNmNIUUN3ME2wMlI{Pjl6IN88US=> M3HLc3NCVkeHUh?=
HT-29 M1y3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP3TWM2OD1yLkK0NlQ5KM7:TR?= MUnTRW5ITVJ?
LB771-HNC NXnKSWVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvqTWM2OD1yLkK1PVE2KM7:TR?= M1zURXNCVkeHUh?=
HT-144 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljnTWM2OD1yLkK2NVkyKM7:TR?= M1Lyc3NCVkeHUh?=
LAN-6 NF3MfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMk[zOFgh|ryP MXLTRW5ITVJ?
EW-18 M{XXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjDTWM2OD1yLkK3NFAyKM7:TR?= NV7rOYtsW0GQR1XS
LS-1034 M3TSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMkexN|Ih|ryP MlHmV2FPT0WU
EW-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnId2RKSzVyPUCuNlg1OzJizszN M4XCcHNCVkeHUh?=
SNU-C1 NHOybWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i4cGlEPTB;MD6yPVMyOyEQvF2= MX3TRW5ITVJ?
RS4-11 NITBOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPTXZVKSzVyPUCuN|M4PThizszN NYnYSVVvW0GQR1XS
ES4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTTXWtTUUN3ME2wMlQyODN6IN88US=> M4DndnNCVkeHUh?=
COLO-320-HSR NILzNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwNEGzOlgh|ryP MknVV2FPT0WU
NB10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwNEW0N|ch|ryP NGfGWVhUSU6JRWK=
BFTC-905 NHHXVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\VTWM2OD1yLkS2O|U5KM7:TR?= MXfTRW5ITVJ?
A375 M2C5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL2bZdKSzVyPUCuOFc3OTdizszN MlHkV2FPT0WU
SJRH30 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwNUC4NlIh|ryP NUHxfJZJW0GQR1XS
NOS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfOTWM2OD1yLkWyNlY4KM7:TR?= Mn7BV2FPT0WU
SIG-M5 NWH0OGZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnrTWM2OD1yLkWzOVU4KM7:TR?= Ml7sV2FPT0WU
DOK M3LZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwNUW2JO69VQ>? M4fpSXNCVkeHUh?=
NB69 NInGT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwNUiyOVch|ryP MX7TRW5ITVJ?
SK-NEP-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwNkCyN|Yh|ryP NVrGUZdFW0GQR1XS
SK-MM-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;X[5JKSzVyPUCuOlU1QTFizszN MkDRV2FPT0WU
NCI-H358 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\vWGlEPTB;MD62O|A5OiEQvF2= NFzufFFUSU6JRWK=
RH-1 NG\WWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HDRWlEPTB;MD63OFg2QSEQvF2= MW\TRW5ITVJ?
NH-12 NUXuOmRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwN{[wOFYh|ryP NGXjNJVUSU6JRWK=
TE-12 NF71d3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGzSWxVUUN3ME2wMlc3PDh4IN88US=> M{jWd3NCVkeHUh?=
COLO-668 NUTNNHRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjqRmVKSzVyPUCuPFQ3PjZizszN NXPrb3duW0GQR1XS
PANC-08-13 MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHjbJlKSzVyPUCuPFY{PzdizszN MlvHV2FPT0WU
HCC2998 NXnMUmpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjI[2dTUUN3ME2wMlg5OjZ|IN88US=> MYPTRW5ITVJ?
ABC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O2NmlEPTB;MD65NFM2OiEQvF2= MkjwV2FPT0WU
ES6 NIO1THlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwOUGwOlYh|ryP NVriTZVoW0GQR1XS
SNU-387 M3XrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwOUmzPVMh|ryP NV7oVWd{W0GQR1XS
CMK M1fwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHDTWM2OD1yLkm5PVI6KM7:TR?= MmrSV2FPT0WU
SJSA-1 M4TCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M124[mlEPTB;MT6wN|Y2OyEQvF2= M{\y[XNCVkeHUh?=
SIMA NEHoOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;JPWlEPTB;MT6wOlgzPSEQvF2= NYLjcVFnW0GQR1XS
ES3 NWDKPFU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vsRmlEPTB;MT6xNlI6PyEQvF2= NGDuPGFUSU6JRWK=
IGROV-1 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[wfGxQUUN3ME2xMlE2PDR2IN88US=> MYTTRW5ITVJ?
MEL-JUSO M3nDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf0TWM2OD1zLkG1O|U6KM7:TR?= MkjDV2FPT0WU
T84 MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwMkC5NVQh|ryP NI\TcGdUSU6JRWK=
CAL-85-1 Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjvVFlKSzVyPUGuNlMyOzhizszN MUXTRW5ITVJ?
RD NIXm[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXnPG9CUUN3ME2xMlI3PDV3IN88US=> NH;pNWlUSU6JRWK=
TE-8 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfRd4FKSzVyPUGuN|E1PjJizszN NGTwdYdUSU6JRWK=
L-363 NGfWbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G4b2lEPTB;MT6zOFIxQCEQvF2= MUfTRW5ITVJ?
EKVX M2TBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwM{S1Olgh|ryP Ml;wV2FPT0WU
SK-MEL-3 NVnTRWFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjqfVM5UUN3ME2xMlQ5PTV4IN88US=> MkDyV2FPT0WU
TGBC24TKB M1TPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHWZ4FKSzVyPUGuOVAyQTNizszN MlPMV2FPT0WU
NCI-H1770 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDRZ5hOUUN3ME2xMlUyOTF|IN88US=> NYH1NXFQW0GQR1XS
HuH-7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFwNkCwPVgh|ryP NGS5cIRUSU6JRWK=
HL-60 M2\6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rxcmlEPTB;MT62OlkzQCEQvF2= NU\STppOW0GQR1XS
TE-1 M{H0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzHNIltUUN3ME2xMlcxQTR3IN88US=> M2TCO3NCVkeHUh?=
LC-2-ad MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPrV4VvUUN3ME2xMlc{QDh5IN88US=> MkjUV2FPT0WU
LB647-SCLC NGTK[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPjbYpKSzVyPUGuO|Y2QDNizszN NVizdWQ{W0GQR1XS
NCI-H2171 NYP5fXk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPrTWM2OD1zLke3O|E3KM7:TR?= M{fKRnNCVkeHUh?=
SK-PN-DW NUDheFRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTVNFRKSzVyPUGuPVEzQThizszN NUTYSXd5W0GQR1XS
MC-IXC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HGeGlEPTB;MT65PFk5KM7:TR?= NGHGfmVUSU6JRWK=
LS-513 NFzqR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DpXGlEPTB;Mj6wOVMxPSEQvF2= NFjZVHdUSU6JRWK=
EW-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJwMEm4OFQh|ryP MWPTRW5ITVJ?
OPM-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHBXotHUUN3ME2yMlExOiEQvF2= NH:ydolUSU6JRWK=
LP-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwMkW4NFch|ryP MmDDV2FPT0WU
LU-134-A M3Hqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1SxVGlEPTB;Mj6yO|ch|ryP NIfVTVRUSU6JRWK=
CP66-MEL M{jSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTKTWM2OD1{LkK5NFE1KM7:TR?= NWTFXldsW0GQR1XS
HCC1143 NWXrPGZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDoTWM2OD1{LkS1N|Y5KM7:TR?= NX22ZpdKW0GQR1XS
LOXIMVI MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe3[HpKSzVyPUKuOlAzOSEQvF2= NX;EVGJ2W0GQR1XS
TE-10 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJwN{C4N|gh|ryP NFnTNotUSU6JRWK=
NCI-H1882 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfI[oJ1UUN3ME2yMlc2OjJ5IN88US=> MWrTRW5ITVJ?
CHP-126 NX\4cZNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CwVGlEPTB;Mj63OlMyPyEQvF2= Mmr3V2FPT0WU
NCI-H1623 NFHROGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJwOUKwNlQh|ryP MXLTRW5ITVJ?
GB-1 NV74SXhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu5b29KSzVyPUKuPVM1ODRizszN M1HLcXNCVkeHUh?=
RCC10RGB MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwOUWyPFEh|ryP NEPkWoxUSU6JRWK=
NCI-H2141 M1;jZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TCN2lEPTB;Mj65Olg6PiEQvF2= NUXuephCW0GQR1XS
GI-ME-N NWm1Wog1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW2TWM2OD1|LkCwOVY2KM7:TR?= NH;OdnhUSU6JRWK=
NCI-H526 NH;5RoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHGO5I6UUN3ME2zMlA1ODh3IN88US=> NUf6c41mW0GQR1XS
NCI-H747 NFPUSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv4UFBKSzVyPUOuNFQ6QTJizszN MnTkV2FPT0WU
SNU-423 M1W0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrnR2FCUUN3ME2zMlIxOzF|IN88US=> MlzvV2FPT0WU
A427 NGO2NVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDUTWM2OD1|LkK1Olk6KM7:TR?= MnPEV2FPT0WU
CAL-12T NHfH[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXKZVJKSzVyPUOuOFA4OTNizszN MVTTRW5ITVJ?
LU-99A MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\YdGlEPTB;Mz60O|ExPSEQvF2= MmHKV2FPT0WU
MS-1 NF6yZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXmTWM2OD1|LkWzOFI6KM7:TR?= M2PVbHNCVkeHUh?=
SK-LU-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTNwN{[yPVUh|ryP M3;yV3NCVkeHUh?=
SW837 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNwN{[zN|Mh|ryP NHvCc21USU6JRWK=
ES8 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULk[oVTUUN3ME2zMlg{QDd5IN88US=> MYrTRW5ITVJ?
MZ2-MEL M{nrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\LOWNKSzVyPUOuPVIxQDZizszN MV3TRW5ITVJ?
TGW MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjaPWtKSzVyPUSuNFE{OTFizszN MWjTRW5ITVJ?
GP5d NX73XXVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHyRo9KSzVyPUSuNFU{PjJizszN NGrLTo1USU6JRWK=
BB49-HNC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDXTWM2OD12LkG1NlE{KM7:TR?= NUfld4lTW0GQR1XS
NB13 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnroTWM2OD12LkK2PFg4KM7:TR?= M{\WUHNCVkeHUh?=
NTERA-S-cl-D1 NXziRXVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrwRY5KSzVyPUSuNlg3OTVizszN NFnNRXpUSU6JRWK=
NCI-H1648 NXnxNnZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwMkm4NVkh|ryP NUHwVI1ZW0GQR1XS
LCLC-103H NUCyR2dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTRwM{KxPVUh|ryP M4DTfnNCVkeHUh?=
LS-411N MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjHcGlKSzVyPUSuOFQ5QDVizszN MmLZV2FPT0WU
NCI-H1092 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DsemlEPTB;ND60OVY5PyEQvF2= NXyzdoxbW0GQR1XS
PANC-10-05 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDlbYtjUUN3ME20MlY6QDRizszN MnzHV2FPT0WU
DK-MG M1LGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfxTWM2OD12LkiwPVM{KM7:TR?= MWrTRW5ITVJ?
OVCAR-5 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fkWmlEPTB;ND64NVIzPiEQvF2= MnvmV2FPT0WU
CAL-39 NXO0Xmg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTRwOEe2O{DPxE1? MnjGV2FPT0WU
TE-441-T NYDtcm9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGOxW2ZKSzVyPUSuPVA2OzdizszN M1XW[XNCVkeHUh?=
MOLT-16 M2rWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;GPWlEPTB;ND65OVI2OyEQvF2= MVfTRW5ITVJ?
MCF7 MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTVwMUS1NVch|ryP Mn7GV2FPT0WU
CAPAN-1 MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTVwMkW3NFch|ryP NUnSdIFVW0GQR1XS
PSN1 M3TCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjhRndKSzVyPUWuNlczOzVizszN NWS5Z284W0GQR1XS
NCI-H292 NFf6PWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf3TWM2OD13LkOwNFQ1KM7:TR?= NILPZplUSU6JRWK=
CPC-N NUjwcVd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjmcFhKSzVyPUWuN|k1OTlizszN MmDnV2FPT0WU
DoTc2-4510 M33Fdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[0TWM2OD13LkS1N|cyKM7:TR?= M1TKR3NCVkeHUh?=
LB1047-RCC M1XVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTVwNUW5N|Mh|ryP NXjLZ5dKW0GQR1XS
MHH-ES-1 NYKyfFViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPvUZZKSzVyPUWuOVk6ODdizszN MXnTRW5ITVJ?
NMC-G1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\wN2lEPTB;NT63NFIzPyEQvF2= MoXDV2FPT0WU
SW1710 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H4O2lEPTB;NT63OFc2OSEQvF2= MWjTRW5ITVJ?
YAPC NYjvOG9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DYUmlEPTB;NT63OlIxOSEQvF2= M3;CNnNCVkeHUh?=
22RV1 M3vMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vVb2lEPTB;NT64NFAyQSEQvF2= MX\TRW5ITVJ?
COLO-679 Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPKVHFKSzVyPUWuPFg6PDhizszN MVTTRW5ITVJ?
TCCSUP NWn0[G5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvrTWM2OD13LkmzNlU6KM7:TR?= MnnyV2FPT0WU
C2BBe1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3CdItzUUN3ME21Mlk{QTdizszN M{nI[XNCVkeHUh?=
TE-15 NF;DfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPiTGdKSzVyPU[uNFY3ODVizszN M1nsbHNCVkeHUh?=
SCLC-21H NEXVXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfqTWM2OD14LkGwPFQ{KM7:TR?= NYnkUnliW0GQR1XS
EoL-1-cell NEDrS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T2O2lEPTB;Nj6xOlU3OyEQvF2= NFPiVHpUSU6JRWK=
NKM-1 NYnsbWtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;hUnRqUUN3ME22MlE3PzFizszN MXzTRW5ITVJ?
NCI-H1304 NWLyZZhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHmVphKSzVyPU[uNlc1OjhizszN NV7u[3l4W0GQR1XS
NB6 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLWZnJEUUN3ME22MlI6PjJ{IN88US=> NV7jNmxNW0GQR1XS
NALM-6 NH;XeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTZwM{OyN{DPxE1? MVjTRW5ITVJ?
NCI-H522 NHHCW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfYTWM2OD14LkOzN|A3KM7:TR?= NXWzcW06W0GQR1XS
MV-4-11 NU\MTmsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfvPVNSUUN3ME22MlM4ODd7IN88US=> MVvTRW5ITVJ?
LB2241-RCC MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf5W|hRUUN3ME22MlM5PjZ5IN88US=> NX7n[I5sW0GQR1XS
NCI-H1417 NFS5OodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m4UmlEPTB;Nj60NFg1PyEQvF2= NYezelVCW0GQR1XS
HT-1197 NIXYN4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i2N2lEPTB;Nj61O|EzOiEQvF2= MXnTRW5ITVJ?
P30-OHK Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorxTWM2OD14Lk[yO|ch|ryP MkLrV2FPT0WU
ALL-PO MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\2N2lEPTB;Nj63NVkyPiEQvF2= MoTFV2FPT0WU
OVCAR-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXkTWM2OD14Lke1OFA2KM7:TR?= NYHTc2ZIW0GQR1XS
HCC2157 M{PCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTZwN{e0O|Uh|ryP NXrQe5lVW0GQR1XS
NCI-H838 NGDwOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTZwOU[0PUDPxE1? MYfTRW5ITVJ?
NCI-H1299 M2H0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTZwOUewPUDPxE1? M1nFPXNCVkeHUh?=
SW954 NHTad3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTdwMkCwOlgh|ryP MWfTRW5ITVJ?
NCI-H441 NH3PfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnUTWM2OD15LkO0NFY2KM7:TR?= NFvafIVUSU6JRWK=
SK-MEL-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXFZYtKSzVyPUeuOFg{PzNizszN M4foVXNCVkeHUh?=
KARPAS-45 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTdwNkW5Nlkh|ryP M1rXXHNCVkeHUh?=
CAL-54 NXz2UVVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnlTWM2OD15LkiyPVc4KM7:TR?= NF;NSlhUSU6JRWK=
KYSE-180 MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XROmlEPTB;Nz64PFk1OSEQvF2= NXXlWoRlW0GQR1XS
NCI-H187 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTdwOUW5OFch|ryP NWPqW2RvW0GQR1XS
RT-112 NEnEc|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvpdGprUUN3ME24MlA6Pjd5IN88US=> NH;wTlRUSU6JRWK=
NCI-H1437 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrRdpNMUUN3ME24MlA6Pzl3IN88US=> NV7tcHdKW0GQR1XS
SNU-449 NIHnSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PoPWlEPTB;OD6yPFI4OiEQvF2= NWC0ZmM4W0GQR1XS
HCC1187 M{Lu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRThwMkmzPVEh|ryP NWjzXJpwW0GQR1XS
NCI-H2030 NU\USYd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP5W21KSzVyPUiuN|c4OTRizszN NVG1e|VsW0GQR1XS
HuO-3N1 NVH0dIM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33QN2lEPTB;OD6zO|g1PCEQvF2= M{\n[XNCVkeHUh?=
COLO-792 NH\oRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7QS|RtUUN3ME24MlQyPTJ5IN88US=> NUPZfmk5W0GQR1XS
MIA-PaCa-2 NVrF[4FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLlTWM2OD16Lki1OVA5KM7:TR?= NYHKb2VnW0GQR1XS
SK-N-FI M13WOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjBVHpKSzVyPUmuNFQzPSEQvF2= NVfqNJZuW0GQR1XS
MMAC-SF NUfjWY9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXQO29KSzVyPUmuNFk4PTFizszN MlPGV2FPT0WU
NCI-H28 MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTlwMUC0Olkh|ryP NGfRZnhUSU6JRWK=
ETK-1 NIXzWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTlwMkm5O|Qh|ryP NGLIfGpUSU6JRWK=
NCI-H1993 M1y5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjkc|BKSzVyPUmuOFQzPjFizszN M{DxR3NCVkeHUh?=
no-11 NFLafFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnJWIxKSzVyPUmuOFcyOiEQvF2= MWnTRW5ITVJ?
ChaGo-K-1 NF3ocWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTTTWM2OD17LkWxOVg{KM7:TR?= NV3OWndqW0GQR1XS
NCCIT MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPvUY5MUUN3ME25MlU{OTZ7IN88US=> MVXTRW5ITVJ?
SAS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfQNld5UUN3ME2xNE4zPDhizszN M3;TTXNCVkeHUh?=
A673 NFnCboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrueo97UUN3ME2xNE4{PzB2IN88US=> NU\oVVY4W0GQR1XS
NCI-H1522 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe1TWM2OD1zMD6zO|A4KM7:TR?= NHr6WFZUSU6JRWK=
NCI-H810 NWLPSGJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:4dmlEPTB;MUCuN|kxPyEQvF2= NGi3NZBUSU6JRWK=
IST-MES1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPlTWM2OD1zMD60OVY1KM7:TR?= NG\4VHlUSU6JRWK=
GR-ST MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjje2VMUUN3ME2xNE42ODJ2IN88US=> M33QWXNCVkeHUh?=
SUP-T1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLXTWM2OD1zMD63N|E4KM7:TR?= NGHVcm5USU6JRWK=
NB5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TIPWlEPTB;MUCuPVAzOiEQvF2= MUjTRW5ITVJ?
MZ1-PC MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPqTWM2OD1zMD65OVcyKM7:TR?= MmTGV2FPT0WU
SK-CO-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFyLkm5N|Eh|ryP M2LnUnNCVkeHUh?=
Capan-2 NGnrR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP5SIlKSzVyPUGxMlMyQThizszN NGjYTGJUSU6JRWK=
697 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPqdYRKSzVyPUGxMlY4PTdizszN M3r2S3NCVkeHUh?=
REH MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq1[nFOUUN3ME2xNU44PDVzIN88US=> M1GwTXNCVkeHUh?=
GI-1 NX61VYZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7vTWM2OD1zMT64OlE2KM7:TR?= NWruTYU5W0GQR1XS
BB65-RCC Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInxfFVKSzVyPUGyMlA6OTZizszN MnLjV2FPT0WU
NCI-H1651 M2DKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF{LkK0O|gh|ryP NGDEUGlUSU6JRWK=
NCI-H1618 NX;uR4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjIdVlKSzVyPUGyMlM6PzZizszN MkHhV2FPT0WU
NCI-H2081 NEDmVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTkOFVXUUN3ME2xNk43OTRzIN88US=> MXHTRW5ITVJ?
GCIY NEnWPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DvfGlEPTB;MUKuO|IyOyEQvF2= NVK4SoNEW0GQR1XS
NY MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fLV2lEPTB;MUOuNFY1OyEQvF2= MlHQV2FPT0WU
PANC-03-27 NX3a[|k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj4TWM2OD1zMz6wPFA4KM7:TR?= MVzTRW5ITVJ?
BHY NF\YU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLJN2JKSzVyPUGzMlIyOjFizszN MXvTRW5ITVJ?
SK-OV-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS0UZJYUUN3ME2xN{4{PzZ|IN88US=> M173ZnNCVkeHUh?=
5637 M1HDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljDTWM2OD1zMz63O|U6KM7:TR?= M3\O[nNCVkeHUh?=
LC-1F Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLDOYpDUUN3ME2xOE4xOzV4IN88US=> NV[yRVA3W0GQR1XS
SNB75 M4DlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2iwOGlEPTB;MUSuNFM5OyEQvF2= M1fXOnNCVkeHUh?=
CHP-212 M3zFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHDOFFKSzVyPUG0MlA1PjRizszN M1fDVnNCVkeHUh?=
HT-1376 NXfrbXUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPCTWM2OD1zND6xNVI3KM7:TR?= NEjLNZNUSU6JRWK=
MONO-MAC-6 NHuzOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXXTWM2OD1zND6xOVAzKM7:TR?= MknlV2FPT0WU
CA46 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\Le2lEPTB;MUSuNVgzPyEQvF2= MnjkV2FPT0WU
SCC-15 M3zGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi4N2JCUUN3ME2xOE42PTh|IN88US=> NWrlN5h6W0GQR1XS
ATN-1 M4HRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\Wd2pKSzVyPUG0MlY3OjdizszN M33mcXNCVkeHUh?=
NCI-H2405 M1fPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDITWM2OD1zND64NVU4KM7:TR?= M3zIZnNCVkeHUh?=
NCI-H716 NFHiNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK2bI1LUUN3ME2xOE45PDl|IN88US=> MorpV2FPT0WU
SW620 NHLz[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF2LkmwNVQh|ryP MYDTRW5ITVJ?
NCI-H226 NV\XT2hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF2LkmwPFUh|ryP NYPJd4Z{W0GQR1XS
SW962 Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33WSWlEPTB;MUSuPVQ{OiEQvF2= MVLTRW5ITVJ?
KYSE-150 NGHkZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7yTWM2OD1zND65OVUh|ryP NGnSNoRUSU6JRWK=
OCUB-M MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\BTWM2OD1zND65PFg{KM7:TR?= MVrTRW5ITVJ?
ES7 MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUizdWxkUUN3ME2xOU4xQTh2IN88US=> NGnpNHJUSU6JRWK=
SW1463 MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fZUGlEPTB;MUWuOFIzOyEQvF2= MWnTRW5ITVJ?
CAKI-1 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzYbGxKSzVyPUG1MlU{PDZizszN M4rDVnNCVkeHUh?=
MKN28 NILuW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLtTWM2OD1zNT61OFc6KM7:TR?= NIf0fW5USU6JRWK=
SW13 NUHEU5dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrWWYg3UUN3ME2xOU43OThizszN NWflfVd2W0GQR1XS
A3-KAW M1[y[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nQWGlEPTB;MUWuPVY6PyEQvF2= MYjTRW5ITVJ?
LU-65 NF:yS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PMe2lEPTB;MUWuPVc3QCEQvF2= NXfQSYZIW0GQR1XS
Calu-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLNZ5JKSzVyPUG2MlA{PjhizszN M3HQTnNCVkeHUh?=
ST486 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF4LkC0N|Eh|ryP M33vb3NCVkeHUh?=
BB30-HNC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPwWnJKSzVyPUG2MlEzPDZizszN NIPxdIFUSU6JRWK=
EGI-1 NIDtR2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHlR3hKSzVyPUG2MlQ1PiEQvF2= NFTxT29USU6JRWK=
SH-4 M2CzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfobHdKSzVyPUG2MlQ4OzFizszN NFrVcoVUSU6JRWK=
MN-60 NV7Ie49xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXFTWM2OD1zNz6yNlk4KM7:TR?= M4PKWXNCVkeHUh?=
MPP-89 MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF5LkK0OVkh|ryP NVfVUHl[W0GQR1XS
A2780 NX\6OnZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm1eGNvUUN3ME2xO{41OTN7IN88US=> NV\Dfm5vW0GQR1XS
Daoy MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF5LkS2PVUh|ryP MX;TRW5ITVJ?
NCI-H2126 NYj2dFJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvxTWM2OD1zNz60O|cyKM7:TR?= MnGyV2FPT0WU
NCI-H1563 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LZZWlEPTB;MUeuOFkyPyEQvF2= M3\QOnNCVkeHUh?=
8-MG-BA MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLNSY5KSzVyPUG3MlY3PDhizszN Ml;kV2FPT0WU
786-0 M1vIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7NTWM2OD1zNz64N|U{KM7:TR?= MmGwV2FPT0WU
AM-38 NIfDUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TsZWlEPTB;MUeuPVMxPiEQvF2= NYLsUY1qW0GQR1XS
COLO-824 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHGPZdVUUN3ME2xPE41PDN4IN88US=> NF65W5lUSU6JRWK=
SK-MEL-30 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;JbmlEPTB;MUiuOVA5OiEQvF2= NGG2[|lUSU6JRWK=
CESS NHTncotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF6Lke2NFkh|ryP NFLtRpNUSU6JRWK=
BL-70 M3r5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjOZ3hKSzVyPUG4MlgyPTZizszN NH;EOZZUSU6JRWK=
NCI-H2170 Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF6LkmxO|kh|ryP NF\0OJpUSU6JRWK=
HT-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HkT2lEPTB;MUiuPVg{KM7:TR?= NX2xVI1wW0GQR1XS
BOKU M1f1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nSfGlEPTB;MUmuNFM5OSEQvF2= NUC5boNIW0GQR1XS
HPAF-II NF3CUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q3fWlEPTB;MUmuN|AyPSEQvF2= MUXTRW5ITVJ?
KGN NHv1cG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTXTWM2OD1zOT60O|Y2KM7:TR?= NH;5[XZUSU6JRWK=
MC-CAR M3nqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\mN25KSzVyPUG5MlY{OTNizszN M3z1dHNCVkeHUh?=
BHT-101 MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PvOmlEPTB;MUmuO|c4KM7:TR?= NYTHd4tJW0GQR1XS
SW1783 MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXhVpdKSzVyPUG5Mlc5ODZizszN MXHTRW5ITVJ?
KP-N-YN MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfxUYx4UUN3ME2yNE4xOjZ{IN88US=> Mk\PV2FPT0WU
LU-165 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLaNohKSzVyPUKwMlU2PzFizszN NF71c5VUSU6JRWK=
GOTO NVrPSVRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJyLk[0OVEh|ryP M3y2W3NCVkeHUh?=
EFM-19 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJzLkC3NVYh|ryP MX3TRW5ITVJ?
CTV-1 NWjHbIdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJzLkGwOVQh|ryP MVHTRW5ITVJ?
HEL M1zxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PEcGlEPTB;MkGuOFIyPiEQvF2= NUfrcGNuW0GQR1XS
SNU-C2B NWntU|NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTE[2JKSzVyPUKxMlQzPiEQvF2= NXKwZpNwW0GQR1XS
ECC4 NESzZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG5fo1KSzVyPUKxMlcxPyEQvF2= NXjSTHNmW0GQR1XS
NEC8 MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj1TWM2OD1{MT64N|Y5KM7:TR?= NEHiSFBUSU6JRWK=
KMOE-2 NFe1SXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S0TWlEPTB;MkGuPFkzOSEQvF2= NX\YcHM4W0GQR1XS
NCI-H524 NWfJb2JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED1WHhKSzVyPUKyMlA5ODhizszN Mk\vV2FPT0WU
WSU-NHL NXi2OohUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH4NllKSzVyPUKyMlE2PzdizszN MWXTRW5ITVJ?
SF126 NF\YSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HhW2lEPTB;MkKuNlQ3QSEQvF2= NILqSHJUSU6JRWK=
HOP-92 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjOW4FKSzVyPUKyMlMyPjdizszN NIDNU5FUSU6JRWK=
CTB-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJ{LkS2O|ch|ryP MlTZV2FPT0WU
KYSE-270 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXrTWM2OD1{Mj65N|U4KM7:TR?= NELlN2ZUSU6JRWK=
SK-MEL-24 NWjvTIZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M133[GlEPTB;MkOuNVg4KM7:TR?= M161cHNCVkeHUh?=
Calu-3 NXXyXnRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJ|LkKxNlgh|ryP Mmi4V2FPT0WU
GAMG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJ|LkKzOlch|ryP M3L6cnNCVkeHUh?=
SW1573 NVTkcHRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXKTWM2OD1{Mz63OFE2KM7:TR?= Mk\WV2FPT0WU
MHH-NB-11 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPScZhKSzVyPUK0MlAyQTRizszN Mk\2V2FPT0WU
TK10 M37LRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\3TWM2OD1{ND61NFE{KM7:TR?= NUXVb2hYW0GQR1XS
LB373-MEL-D NHzFU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWmyWWdNUUN3ME2yOE43ODZ2IN88US=> NELES3RUSU6JRWK=
KALS-1 NFfMW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LjOmlEPTB;MkSuO|MzPyEQvF2= M4PnTnNCVkeHUh?=
HUTU-80 NWjTOXc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ3LkiwN|Ih|ryP M{HUdnNCVkeHUh?=
HuP-T3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljiTWM2OD1{Nj6xOlc1KM7:TR?= M1HVcnNCVkeHUh?=
OE19 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm3RZlKSzVyPUK2MlIyPTNizszN NYHDNmJwW0GQR1XS
J82 M3TvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf4TWM2OD1{Nj6yOFcyKM7:TR?= Mlz5V2FPT0WU
DU-4475 NUPGO|ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ4LkO4NVkh|ryP MWfTRW5ITVJ?
DMS-53 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;ifmlEPTB;Mk[uOVE{QCEQvF2= Ml3yV2FPT0WU
COLO-741 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP3RlhMUUN3ME2yOk45OzR2IN88US=> NVj3ZmdVW0GQR1XS
SW48 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXmeGtKSzVyPUK2Mlg5OiEQvF2= M1LldnNCVkeHUh?=
IGR-1 MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnCNnVwUUN3ME2yOk46OzN2IN88US=> M4TKNHNCVkeHUh?=
639-V MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq5d|RpUUN3ME2yO{4xOjR3IN88US=> M1nnVHNCVkeHUh?=
LK-2 M{Xu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XMN2lEPTB;MkeuOFE1OSEQvF2= MVLTRW5ITVJ?
NCI-H2347 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\4TWM2OD1{Nz65Olk6KM7:TR?= MliyV2FPT0WU
NCI-H2228 M2nMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfXO29KSzVyPUK4MlA6ODVizszN MlHGV2FPT0WU
LS-123 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\VXmlEPTB;MkiuNVI3OiEQvF2= NHPte3JUSU6JRWK=
U031 M2\I[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPyR|M1UUN3ME2yPE4zPTJizszN NGDPUlhUSU6JRWK=
NCI-H1792 NITzR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vYRmlEPTB;MkiuOFczOSEQvF2= MlLlV2FPT0WU
NCI-H2087 M1rLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor5TWM2OD1{OD63OVUzKM7:TR?= NFX0VZJUSU6JRWK=
NCI-H2342 NVXpPZliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PvTmlEPTB;MkmuOVIxQCEQvF2= M1;4cnNCVkeHUh?=
SW626 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ7Lke1OkDPxE1? NIDEXYtUSU6JRWK=
LB2518-MEL Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ7LkixOUDPxE1? NVfLRnF2W0GQR1XS
RXF393 NH6xe5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNyLkC5OVIh|ryP MVPTRW5ITVJ?
LC4-1 NGjCfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHLTWM2OD1|MD6zNFkzKM7:TR?= MWTTRW5ITVJ?
NCI-H1694 MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;4[JFJUUN3ME2zNE43PjJ2IN88US=> NXTj[|l5W0GQR1XS
K5 MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr6cllKSzVyPUOwMlk4ODJizszN MlviV2FPT0WU
HDLM-2 M{nFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlKxTWM2OD1|MD65O|I2KM7:TR?= NIK4S5NUSU6JRWK=
BCPAP NGq4[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjOTWM2OD1|MT64N|c6KM7:TR?= M{f5fnNCVkeHUh?=
BC-3 NE\DcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN{LkG0NFMh|ryP NV\Nd2FIW0GQR1XS
LB996-RCC NH;QSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnVZXZSUUN3ME2zNk4zOzV6IN88US=> NGLF[GFUSU6JRWK=
NCI-H2009 NYrFT|liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPvTWM2OD1|Mj60PVgyKM7:TR?= NW\oOYU4W0GQR1XS
HTC-C3 NVfCc5FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfNTWM2OD1|Mz63OVE6KM7:TR?= NFPWbnRUSU6JRWK=
LAMA-84 MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH6UZlKSzVyPUO0MlQ1ODdizszN NEPLT5BUSU6JRWK=
CCRF-CEM NUfpeG14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN2LkW3NVUh|ryP NV3pU4w3W0GQR1XS
AN3-CA MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG1TWM2OD1|NT6wOVY5KM7:TR?= MkDDV2FPT0WU
NCI-H1734 M3X4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTN3LkK1OlEh|ryP MnXpV2FPT0WU
Ca-Ski NH7qd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnTVGlIUUN3ME2zOU41OTBzIN88US=> MkjRV2FPT0WU
U-266 NGq3RpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXtTWM2OD1|NT62NVE1KM7:TR?= NGjHb5hUSU6JRWK=
SBC-5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz5W2lYUUN3ME2zOU44PzhzIN88US=> NW\yVJdoW0GQR1XS
GT3TKB NH\RNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK4fXRIUUN3ME2zO{4yOTVizszN NUTafXlMW0GQR1XS
MDA-MB-175-VII MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3yzXWlEPTB;M{euNlI1QCEQvF2= NELuZZpUSU6JRWK=
PFSK-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlviTWM2OD1|Nz6yOFM2KM7:TR?= NX62UWVtW0GQR1XS
IMR-5 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTN5LkK0PFch|ryP NGOyTGtUSU6JRWK=
Daudi NGHk[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjvbJp{UUN3ME2zO{4{PTl5IN88US=> NVLobnBKW0GQR1XS
A498 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjUTWM2OD1|Nz63NlE5KM7:TR?= MUnTRW5ITVJ?
SCC-4 NX24SY92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTN5Lke4OFMh|ryP M2S1TXNCVkeHUh?=
COLO-680N MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPqTWM2OD1|OD6yPFg2KM7:TR?= MVnTRW5ITVJ?
SK-MES-1 M3r5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz2TWM2OD1|OD6zNlE2KM7:TR?= M1zwfHNCVkeHUh?=
SR M3Tn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrteFdKSzVyPUO4MlU1QTVizszN NHPxUpJUSU6JRWK=
LNCaP-Clone-FGC NHLJSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTN6LkW2N|ch|ryP M4ezfXNCVkeHUh?=
SK-HEP-1 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q0cGlEPTB;M{iuO|gzOiEQvF2= NFTLVIlUSU6JRWK=
BPH-1 M{[5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnzNGtKSzVyPUO4Mlg{OjlizszN MU\TRW5ITVJ?
NCI-H1755 NIr3R4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;JbotKSzVyPUO5MlU5OTdizszN MmTVV2FPT0WU
LXF-289 M4DJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTN7LkiwPFQh|ryP NIXuZ|RUSU6JRWK=
SW1088 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLKTWM2OD12MD6yNVA4KM7:TR?= M4jWO3NCVkeHUh?=
MOLT-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCwPYFnUUN3ME20NE4zQTBzIN88US=> Mke5V2FPT0WU
AsPC-1 M1TCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRyLkS1PFMh|ryP NV3SemZEW0GQR1XS
HOP-62 NHq4[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PwemlEPTB;NECuOlU3QCEQvF2= MWfTRW5ITVJ?
A172 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILsSVBKSzVyPUSwMlg2OTFizszN NE\KO2pUSU6JRWK=
SN12C MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq3dmdsUUN3ME20NE46Ozh3IN88US=> NYXVU5FxW0GQR1XS
MDA-MB-231 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHQZpZKSzVyPUSwMlk5QThizszN MlP5V2FPT0WU
RPMI-2650 M1nyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nBPWlEPTB;NEGuNVU6OyEQvF2= M4e0VXNCVkeHUh?=
KYSE-140 MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M171c2lEPTB;NEGuPFEzOyEQvF2= NUfwZmdLW0GQR1XS
KINGS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnJUWJKSzVyPUSyMlQ3QTdizszN MWfTRW5ITVJ?
HSC-3 NIDGVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHiTWM2OD12Mj62OlYyKM7:TR?= NVr5NVFKW0GQR1XS
PC-14 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTR|LkG4PFIh|ryP NFLmelFUSU6JRWK=
COR-L105 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTR|Lk[1NFIh|ryP NIjEclBUSU6JRWK=
BE-13 M1P3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrQVGFoUUN3ME20OE4zOzdzIN88US=> MmDOV2FPT0WU
NCI-H661 NXrvVldXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHiXFBsUUN3ME20OE4zQTV6IN88US=> NFTwV2dUSU6JRWK=
IST-MEL1 M2WzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKwZ2RKSzVyPUS0MlM2QTlizszN MofUV2FPT0WU
HCC1806 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzDTWM2OD12ND61PFc{KM7:TR?= MmC5V2FPT0WU
COLO-800 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTud3VzUUN3ME20OE45PDV|IN88US=> MWLTRW5ITVJ?
IST-SL2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfpbVRKSzVyPUS1MlEzPDdizszN MXvTRW5ITVJ?
8305C NEPOT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;CeHJKSzVyPUS1MlMxQSEQvF2= NHXOVGJUSU6JRWK=
UACC-62 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX6RVVuUUN3ME20Ok4zQDd3IN88US=> NVnneZpmW0GQR1XS
COR-L23 M3f2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPRT2VKSzVyPUS3MlE6QSEQvF2= M122dnNCVkeHUh?=
EFE-184 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;VWmFKSzVyPUS3MlM5QCEQvF2= MWTTRW5ITVJ?
DMS-114 NIPYPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P1TWlEPTB;NEeuOFE1QSEQvF2= M3;tUXNCVkeHUh?=
KYSE-520 M33U[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTR6LkWzNVUh|ryP MlfPV2FPT0WU
SNG-M NIXQcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvFWYlKSzVyPUS5MlQ{PCEQvF2= MX3TRW5ITVJ?
A2058 NF73eZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLRSIJRUUN3ME20PU41QDh3IN88US=> NIjGOZFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01186861 Completed Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy Astellas Pharma Inc March 4 2011 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01672736 Terminated Multiple Myeloma University Health Network Toronto|Multiple Myeloma Research Consortium|Astellas Pharma Inc September 2012 Phase 1|Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID